MedTrace Logo

Salvage mFOLFOX in BTC After Failure of Gemcitabine

NCT01127555 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-10-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of mFOLFOX (5-fluorouracil, leucovorin, oxaliplatin)as salvage therapy in patients with unresectable biliary tract cancer who had failed gemcitabine.

Conditions

  • Unresectable Biliary Tract Cancer

Interventions

DRUG

5-fluorouracil, leucovorin, oxaliplatin

D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks

Sponsors & Collaborators

  • Gyeongsang National University Hospital

    collaborator OTHER

  • Dong-A University Hospital

    collaborator OTHER

  • Samsung Medical Center

    collaborator OTHER

  • Chung-Ang University

    lead OTHER

Principal Investigators

  • In Gyu Hwang, M.D. · Chung-Ang University Yongsan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-06-30
Completion
2013-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01127555 on ClinicalTrials.gov